eli lilly retatrutide trials ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Eli Lilly's obesity drug retatrutide

S.NielsenO

And TRANSCEND-T2D-1, part of a separate three-trial diabetes-specific program, confirmed -2.0% HbA1c reduction and 16.8% weight loss in 537 type 2 diabetes patients (topline March 2026, published in The Lancet, June 2026)

Some sources report stability for up to 56 days, but 28 days is a safe guideline

Olympus, Tokyo, Japan) and continuously superfused at a flow speed of 1 mL/min with a bath solution containing 140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose, adjusted to pH 7.4 with NaOH

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model

Additional important aspects are the benefits of increased levels of E